Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 1/2

CAR T Cell Therapy Targeting CD7 in Blood Cancers

Tests CD7-targeted CAR T cells in people with CD7-positive T-cell leukemia, lymphoma or myeloid leukemia.

Key facts

Who runs it
Shenzhen Geno-Immune Medical Institute
Where
Shenzhen, ChinaSee the site
Trial code
Registry title
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
30 people, planned
Starts
31 Dec 2026
Expected to end
31 Dec 2030
Type of study
Interventional
Treatments tested
  • CD7-specific CAR gene-engineered T cells
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with blood cancers whose cancer cells carry CD7, who can have a CAR T cell treatment made from their own cells.

Age
From 6 months to 75 years.
Sex
All sexes can join.
Disease stage
T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma, acute myeloid leukemia or NK cell lymphoma. CD7 or other surface markers must be confirmed in the cancer cells.
Earlier treatment
No earlier gene therapy products. No glucocorticoid taken for the whole body within one week before joining.
Biomarker or test result
CD7 or additional surface antigens confirmed on the cancer cells by staining or flow cytometry.

Main reasons for not taking part

  • Known HIV or hepatitis C virus (HCV) infection
  • Pregnant or nursing women
  • Active infection that is not controlled by treatment
  • Severe illness that would stop the trial plan from being followed
  • Earlier treatment with any gene therapy product

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age older than 6 months
  • Confirmed expression of CD7 or additional surface antigens in the cancer cells by immuno-histochemical staining or flow cytometry
  • Karnofsky performance status (KPS) score is higher than 80 and life expectancy > 3 months
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 × upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg/dL
  • Hgb≥80g/L
  • No cell separation contraindications
  • Abilities to understand and the willingness to provide written informed consent

Who cannot take part

  • Use of glucocorticoid for systemic therapy within one week prior to entering the trial
  • Previous treatment with any gene therapy products
  • Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection
  • Active bacterial, fungal or viral infection not controlled by adequate treatment
  • Known HIV or hepatitis C virus (HCV) infection
  • Pregnant or nursing women may not participate
  • Patients, in the opinion of investigators, may not be able to comply with the study

Where in China

  • Shenzhen Geno-immune Medical InstituteShenzhen, ChinaContact: Lung-Ji Chang, Ph.DNo longer taking part

About the trial

What the trial wants to find out

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells. The study also aims to learn more about the function of CD7 CAR T cells and their persistence in patients of hematological malignancies.

The group in the trial

  • Single armTreatment being tested

    Multiple CAR T cells to treat CD7-positive hematological malignancies

    Treatment: CD7-specific CAR gene-engineered T cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies
Plain-language title
CAR T Cell Therapy Targeting CD7 in Blood CancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 November 2026